A Phase 2 interventional study of ZD4054 10 mg and ZD4054 15 mg in Prostatic Neoplasms and Metastases, Neoplasm, sponsored by AstraZeneca. Completed at 2 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-10-31.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 53rd largest by enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2003, is one of 16 in phase 2, and was the 1st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Austria, Brazil and 18 more countries
Ages 18+ · Men only
AstraZeneca · Sites in United States, Australia, Germany and 4 more countries
Ages 18–99 · Men only
AstraZeneca · Sites in United States, Australia, Korea, Republic of
Ages 18–100 · Men only
AstraZeneca · Sites in United States, Australia, Austria and 21 more countries
Ages 18+ · Men only
AstraZeneca · Sites in United States, Brazil, China and 7 more countries
Ages 18–130 · Men only
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 27 · Phase 3 17 · Phase 4 4
First in 1994; this study’s year is marked. 8 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 110 across the 60 interventional studies, 310 across the 29 observational. Of the 58 that completed or were terminated, 11 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
8 of the studies in Prostatic Neoplasms by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06120491Phase 3AstraZenecaSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | 2027-09-30 |
| NCT06267729AstraZenecaStudy of AZD0754 in Participants With Metastatic Prostate Cancer | 2026-11-24 |
| NCT06402331Fusion Pharmaceuticals Inc.FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 2026-12-23 |
| NCT06380738AstraZenecaReal-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) | 2027-02-14 |
| NCT07560215AstraZenecaPROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian Cohort | 2027-03-31 |
Add all 8 to your calendar (.ics) → With an account.
Among the 91 studies in Prostatic Neoplasms by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine the safest dose of ZD4054 (Zibotentan)in men with prostate cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 x 10 mg oral tablets once daily
Drug: ZD4054 10 mg
1 x 10 mg + 2 x 2.5 mg oral tablets once daily
Drug: ZD4054 15 mg
2 x 10 mg + 1 x 2.5 mg oral tablets once daily
Drug: ZD4054 22.5 mg
1 x 10 mg oral tablets once daily
Also known as: Zibotentan,
1 x 10 mg + 2 x 2.5 mg oral tablets once daily
Also known as: Zibotentan
2 x 10 mg + 2 x 2.5 mg oral tablets once daily
Also known as: Zibotentan
Dose Limiting Toxicities (DLTs)
DLT is defined as experiencing Common Toxicity Criteria (CTC) grade 3 or 4 headache with onset within 24 h of receiving ZD4054, CTC grade 2 rhinitis leading to the withdrawal of the subject, or other CTC grade 3 or 4 toxicity that was considered to be related to ZD4054 treatment. The numbers of patients with a DLT are reported.
Time frame: Baseline to Day 29.
Total Prostate Specific Antigen (PSA) Concentration
Total Prostate Specific Antigen (PSA) concentration at Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2).
Time frame: Baseline to Day 15.
Change in Total Prostate Specific Antigen (PSA)
Percentage change in total Prostate Specific Antigen (PSA) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100
Time frame: Baseline to Day 15.
Change in Serum Concentration of Bone Alkaline Phosphatase (ALP)
Percentage change in serum concentration of Bone Alkaline Phosphatase (ALP) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100
Time frame: Baseline to Day 15.
Change in Serum Concentration of Procollagen Type I N Propeptide (PINP)
Percentage change in serum concentration of Procollagen Type I N Propeptide (PINP) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100
Time frame: Baseline to Day 15.
Change in Serum Concentration of C-Terminal Telopeptide of Type I Collagen (CTx)
Percentage change in serum concentration of C-Terminal Telopeptide of Type I Collagen (CTx) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100
Time frame: Baseline to Day 15.
Change in Urine Concentration of Type I Collagen-Cross Linked N Telopeptide (NTx)
Percentage change in urine concentration of Type I Collagen-Cross Linked N Telopeptide (NTx) (nmol BCE/mmol Creatinine) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100
Time frame: Baseline to Day 15.
22 male patients with metastatic prostate cancer and rising Prostate Specific Antigen (PSA) levels were recruited from 11th June 2003 (last subject completed on 31st October 2005). This study was conducted in 2 centres in the United States.
| Milestone | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| Started | 3 | 10 | 3 |
| Completed | 3 | 8 | 0 |
| Not completed | 0 | 2 | 3 |
| Withdrew: Adverse event | 0 | 1 | 2 |
| Withdrew: Erroneously reported discont. criteria | 0 | 0 | 1 |
| Withdrew: Disease progression | 0 | 1 | 0 |
| Milestone | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| Started | 3 | 6 | 0 |
| Completed | 3 | 6 | 0 |
| Not completed | 0 | 0 | 0 |
DLT is defined as experiencing Common Toxicity Criteria (CTC) grade 3 or 4 headache with onset within 24 h of receiving ZD4054, CTC grade 2 rhinitis leading to the withdrawal of the subject, or other CTC grade 3 or 4 toxicity that was considered to be related to ZD4054 treatment. The numbers of patients with a DLT are reported.
| Participants | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| Dose Limiting Toxicities (DLTs) | 0 | 0 | 2 |
Total Prostate Specific Antigen (PSA) concentration at Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2).
| ng/ml | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| Total Prostate Specific Antigen (PSA) Concentration | 98.454 (78.00 to 142.60) | 62.366 (6.00 to 448.90) | 56.550 (36.80 to 86.90) |
Percentage change in total Prostate Specific Antigen (PSA) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100
| Percentage Change | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| Change in Total Prostate Specific Antigen (PSA) | 2.235 ± 15.445 | 10.986 ± 21.345 | 18.404 ± 30.132 |
Percentage change in serum concentration of Bone Alkaline Phosphatase (ALP) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100
| Percentage Change | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| Change in Serum Concentration of Bone Alkaline Phosphatase (ALP) | -6.161 ± 9.616 | -9.197 ± 12.220 | -9.182 ± 10.644 |
Percentage change in serum concentration of Procollagen Type I N Propeptide (PINP) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100
| Percentage Change | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| Change in Serum Concentration of Procollagen Type I N Propeptide (PINP) | 7.865 ± 14.625 | 20.681 ± 44.217 | 113.012 ± 51.302 |
Percentage change in serum concentration of C-Terminal Telopeptide of Type I Collagen (CTx) (ng/mL) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100
| Percentage Change | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| Change in Serum Concentration of C-Terminal Telopeptide of Type I Collagen (CTx) | -13.832 ± 19.003 | 44.855 ± 94.876 | 20.386 ± 31.094 |
Percentage change in urine concentration of Type I Collagen-Cross Linked N Telopeptide (NTx) (nmol BCE/mmol Creatinine) from baseline to Day 15 (14 doses of study treatment per patient - no dose was administered on Day 2). Percentage change = \[(measure at Day 15 - measure at baseline)/measure at baseline\]\*100
| Percentage Change | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| Change in Urine Concentration of Type I Collagen-Cross Linked N Telopeptide (NTx) | -25.213 ± 15.389 | 2.154 ± 41.900 | -5.942 ± 34.344 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ZD4054 10 mg | — | 0/3 (0%) | 3/3 (100%) |
| ZD4054 15 mg | — | 2/10 (20%) | 10/10 (100%) |
| ZD4054 22.5 mg | — | 2/3 (66.7%) | 3/3 (100%) |
| Event | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| HeadacheNervous system disorders | 0/3 | 0/10 | 1/3 |
| Intraventricular HaemorrhageNervous system disorders | 0/3 | 0/10 | 1/3 |
| SyncopeNervous system disorders | 0/3 | 0/10 | 1/3 |
| Rectal HaemorrhageGastrointestinal disorders | 0/3 | 1/10 | 0/3 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 1/10 | 0/3 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 0/3 | 1/10 | 0/3 |
| Back PainMusculoskeletal and connective tissue disorders | 0/3 | 1/10 | 0/3 |
| Pitting OedemaGeneral disorders | 0/3 | 1/10 | 0/3 |
| Event | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg |
|---|---|---|---|
| FatigueGeneral disorders | 0/3 | 4/10 | 3/3 |
| HeadacheNervous system disorders | 2/3 | 9/10 | 3/3 |
| Oedema PeripheralGeneral disorders | 0/3 | 9/10 | 1/3 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/3 | 2/10 | 2/3 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 1/3 | 1/10 | 2/3 |
| Sinus CongestionRespiratory, thoracic and mediastinal disorders | 0/3 | 2/10 | 2/3 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/10 | 0/3 |
| TinnitusEar and labyrinth disorders | 1/3 | 0/10 | 0/3 |
| CataractEye disorders | 1/3 | 0/10 | 0/3 |
| ConstipationGastrointestinal disorders | 1/3 | 0/10 | 0/3 |
| Age Continuous(Years) | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg | Total |
|---|---|---|---|---|
| Overall | 72.3 ± 3.21 | 64.6 ± 9.72 | 66.3 ± 8.08 | 66.4 ± 8.72 |
| Sex: Female, Male(Participants) | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 3 | 10 | 3 | 16 |
| Race/Ethnicity, Customized(Participants) | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg | Total |
|---|---|---|---|---|
| Caucasian | 3 | 9 | 3 | 15 |
| Black | 0 | 1 | 0 | 1 |
| Oriental | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 |
| Height(Centimeters (cm)) | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg | Total |
|---|---|---|---|---|
| Mean | 177.33 ± 4.51 | 177.10 ± 8.02 | 176.33 ± 5.03 | 177 ± 6.69 |
| Weight(Kilograms (kg)) | ZD4054 10 mg | ZD4054 15 mg | ZD4054 22.5 mg | Total |
|---|---|---|---|---|
| Mean | 87.33 ± 19.035 | 107.8 ± 21.060 | 103.00 ± 35.595 | 103.06 ± 23.405 |
The record gives a start of Jun 2003, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 6 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ZD4054